Aulos Bioscience
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
700 Larkspur Landing Cir Ste 108, Larksp...Phone Number
(212) 213-0006Website
www.aulosbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos was created by ATP, a leading life science venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, to initially develop unique IL2 targeting antibodies that it believes have the potential to become best-in-class treatments for solid tumors.Explore more
Aulos Bioscience Org Chart
LR
Chief Financial Officer
JV
Chief Marketing Officer, Aulos Bioscience
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aulos Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Aulos Bioscience is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Aulos Bioscience has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Aulos Bioscience recently announced quarterly report
Product Launch: Get notified when Aulos Bioscience launches new products
Congratulate Masked Content for being promoted to Masked Content at Aulos Bioscience
Aulos Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Aulos Bioscience has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Aulos Bioscience had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Aulos Bioscience
Find 2 more new buyers
Compare Similar Companies to Aulos Bioscience
Compare insights from companies similar to Aulos Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aulos Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aulos Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aulos Bioscience.
Aulos Bioscience financials insights
Gather financial insights about Aulos Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$60M
Aulos Bioscience Tech Stack
A closer look at the technologies used by Aulos Bioscience
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
Aulos Bioscience News & Media
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of immune-activating antibody therapeutics, today announced dosing of its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase 2 expansion cohort focused on second-line treatment of melanoma. This new cohort is part of Aulos’ Phase 1/2 clinical trial of AU-007 in patients with unresectaAulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data from the Phase 2 portion of its Phase 1/2 clinical trial of AU-007 at the American Association for Cancer Research (AACR) Annual Meeting. The presentation will focus on promising results for AU-007 in second-line treatment of melanoma. AU-007 is a human IgG1 monoclonaAulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced dosing of the first patient with AU-007, avelumab, a PD-L1 antibody with Fc effector function, and low-dose, subcutaneous aldesleukin in a Phase 2 cohort focused on the second-line treatment of PD-L1+ non-small cell lung cancer (NSCLC). The Phase 2 cohort is a clinical trial collaboration with AreStrong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 dose escalation and cohort expansion study of AU-007. The data will be presented in a poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston, Texas. Preliminary Phase 2 data reveal that a combination of AU-007 and low-dose,
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Aulos Bioscience
Sign Up For FreeTo access detailed company insights
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos was created by ATP, a leading life science venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, to initially develop unique IL2 targeting antibodies... Read More
